Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group
Blood (2003) 101 (2): 420–424.
Currently there are no citedby results. Try again later.
